Evorpacept (ALX148) + Cetuximab + Pembrolizumab
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microsatellite Stable Metastatic Colorectal Cancer
Conditions
Microsatellite Stable Metastatic Colorectal Cancer
Trial Timeline
Jul 28, 2022 → Mar 1, 2026
NCT ID
NCT05167409About Evorpacept (ALX148) + Cetuximab + Pembrolizumab
Evorpacept (ALX148) + Cetuximab + Pembrolizumab is a phase 2 stage product being developed by Eli Lilly for Microsatellite Stable Metastatic Colorectal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05167409. Target conditions include Microsatellite Stable Metastatic Colorectal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05167409 | Phase 2 | Active |
Competing Products
11 competing products in Microsatellite Stable Metastatic Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| eFT508 + Avelumab | eFFECTOR Therapeutics | Phase 2 | 44 |
| grapiprant + grapiprant and pembrolizumab | Merck | Phase 1 | 33 |
| Bevacizumab + Capecitabine + Pembrolizumab | Merck | Phase 2 | 52 |
| MK-3475 + INCB024360 | Merck | Phase 1/2 | 41 |
| AMG 436 | Amgen | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| Copanlisib + Nivolumab | Bristol Myers Squibb | Phase 1/2 | 40 |
| Ipilimumab + Nivolumab + Cobimetinib + Daratumumab + BMS-986016 | Bristol Myers Squibb | Phase 2 | 51 |
| Nivolumab + Relatlimab | Bristol Myers Squibb | Phase 2 | 51 |
| Balstilimab + Botensilimab | Agenus | Phase 2 | 44 |